Turning patient needs into breakthroughs
Axsome Therapeutics (axsome.com) earns a Brand Analyzer score of 76 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 4155 Healthcare brands analyzed, Axsome Therapeutics ranks in the 61st percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 85/100, Digital Presence 94/100, Visual Identity 97/100, Messaging Clarity 100/100, Trust Foundation 87/100, AI Discoverability 75/100, Brand Authority 21/100.
Axsome Therapeutics is an American biopharmaceutical company founded in 2012 and headquartered in New York City. It develops innovative treatments for central nervous system (CNS) conditions that lack effective therapies, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Its pipeline includes products such as AXS-05, AXS-12, and AXS-14, aimed at improving outcomes for patients and supporting healthcare providers who treat these conditions.
| Brand Name | Axsome Therapeutics |
|---|---|
| Domain | axsome.com |
| Industry | Healthcare |
| Founded | 2012 |
| Headquarters | New York City |
| Main Competitors | Jazz Pharmaceuticals, Harmony Biosciences (72/100), Sage Therapeutics (76/100), Supernus Pharmaceuticals, Biogen (78/100), Otsuka Pharmaceutical, Eli Lilly (78/100), Amgen (82/100) |
Moz Domain Authority 46/100 vs category average 37 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #283,937 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14.…" (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 3 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt mentions GPTBot, ClaudeBot, Google-Extended - all allowed - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), Instagram, GitHub; no detected presence on LinkedIn, Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Axsome Therapeutics scores 40/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Axsome Therapeutics has a limited AI-visibility profile at 40/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #283,937 (Tranco) and a Moz Domain Authority of 46/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Axsome Therapeutics from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Axsome Therapeutics?", Claude could identify the brand as of August 2026. Axsome Therapeutics is a biopharmaceutical company focused on developing therapies for central nervous system disorders, including depression, migraine, and Alzheimer's-related agitation. It's known for bringing several novel CNS drugs through FDA approval by repurposing and comb Best known for Developing Auvelity, an oral rapid-acting treatment for major depressive disorder.
When asked "Best brands similar to Axsome Therapeutics?", Claude would recommend Axsome Therapeutics as of August 2026. It's a notable name in CNS-focused biopharma with multiple approved drugs, so it would come up naturally in discussions of companies innovating in depression and neurological treatments.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Axsome Therapeutics's main competitors include Jazz Pharmaceuticals, Harmony Biosciences (72/100), Sage Therapeutics (76/100), Supernus Pharmaceuticals, Biogen (78/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Axsome Therapeutics and Amgen are competitors in Healthcare. Brand Analyzer scores Axsome Therapeutics at 76/100 and Amgen at 82/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Axsome Therapeutics include Jazz Pharmaceuticals, Harmony Biosciences (72/100), Sage Therapeutics (76/100), Supernus Pharmaceuticals, Biogen (78/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Axsome Therapeutics offers pipeline drug candidates including AXS-05, AXS-12, and AXS-14, which are being developed as treatments for CNS conditions such as depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia.
Sources: Axsome Therapeutics official site
Axsome Therapeutics is an American biopharmaceutical company founded in 2012 and headquartered in New York City. It focuses on developing treatments for central nervous system (CNS) disorders that currently have limited or no effective therapeutic options.
Sources: Axsome Therapeutics official site
Axsome Therapeutics has limited AI-search visibility, scoring 40/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 49, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Axsome Therapeutics official site
Axsome Therapeutics was founded in 2012. Axsome Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Axsome Therapeutics is headquartered in New York City. Axsome Therapeutics operates in the Healthcare category.
Sources: Wikidata
Axsome Therapeutics develops innovative pharmaceutical treatments targeting CNS conditions such as depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Its pipeline includes drug candidates like AXS-05, AXS-12, and AXS-14, which are designed to address underserved patient populations with these disorders.
Sources: Axsome Therapeutics official site
Axsome Therapeutics scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Axsome Therapeutics official site
Axsome Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Axsome Therapeutics official site
Axsome Therapeutics' treatments are intended for patients suffering from CNS conditions such as depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia, as well as the healthcare providers who diagnose and treat these patients.
Sources: Axsome Therapeutics official site
Axsome Therapeutics is known for developing novel therapies aimed at CNS conditions lacking adequate treatment options, particularly its pipeline products AXS-05, AXS-12, and AXS-14, which target depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia.
Sources: Axsome Therapeutics official site
Ranked closest to Axsome Therapeutics: Autoscribe Informatics (76/100), Augmedics (76/100), BetterRX (76/100), Bluesight (76/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).